Percutaneous cryoablation of kidney cancer under ultrasound and CT navigation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Currently, various types of partial nephrectomy are the gold standard for the treatment of early-stage (T1a) renal cell cancer (RCC), but there is a category of patients who cannot undergo surgical procedure under general anesthesia, often due to severe comorbidities. Ablative technologies are an alternative to partial nephrectomy, in particular percutaneous cryoablation (PCA).

Aim. To evaluate the safety and efficiency of PCA of RCC (cT1a) under ultrasound and computed tomography (CT) guidance, as well as overall, disease-free and cancer-specific survival.

Materials and methods. After receiving approval from the local ethics committee, a total of 59 patients with RCC was undergone to PCI at the Institute of Urology and Human Reproductive Health of the First Moscow State Medical University named after I.M. Sechenov. In the period from 2015 to 2017, PCI under ultrasound guidance was performed in 27 patients. The average age of the patients was 66 years (48–83), the average tumor size was 29 mm (14–36). The Charlson comorbidity index was 7 (5–10). In the period from 2018 to 2022, PCI for RCC was performed in 32 patients. The average age was 68 years (46–89), while the average tumor size was 24 mm (8–38). The Charlson comorbidity index was 7 (4–12). The study included patients with histologically confirmed RCC with a tumor size of up to 4 cm.

Results. There were four recurrences diagnosed by ultrasound. Two patients underwent repeated PCI, while in the remaining cases laparoscopic partial nephrectomy was done. Six-year overall, disease-free and cancer-specific survival was 96%, 85% and 100%, respectively. On CT, four relapses were diagnosed. Repeat PCI was done in two patients, and laparoscopic partial nephrectomy was performed in other two cases. In one patient, intraoperative bleeding was noted during the insertion of cryoneedles, due to which the procedure was aborted. Bleeding was stopped conservatively. Three- overall, disease-free and cancer-specific survival was 97%, 88% and 100%, respectively.

Conclusions. PCI under ultrasound and CT guidance showed comparable efficacy in the treatment of RCC, however, to reduce the radiation dose, it is reasonable to use a combination of imaging methods.

Full Text

Restricted Access

About the authors

A. I. Salpagarova

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Author for correspondence.
Email: salpagarova01@inbox.ru

research intern at the Institute of Urology and Reproductive Health, Institute of the Clinical Medicine named after N.V. Sklifosovsky

Russian Federation, Moscow

S. X. Ali

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: ali_s_kh@staff.sechenov.ru

urologist, Ph. D., associate professor at the Institute of Urology and Reproductive Health

Russian Federation, Moscow

D. V. Chinenov

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: chinenov_d_v@staff.sechenov.ru

Ph.D., Head of the Department of Oncourology of the University Clinic Hospital No. 2, associate professor at the Institute for Urology and Human Reproductive Health

Russian Federation, Moscow

Z. K. Dzhalaev

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: dzhalaev.zurab@mail.ru

urologist, Ph. D. student at the Institute for Urology and Human Reproductive Health

Russian Federation, Moscow

A. D. Damiev

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: damievakhmed@mail.ru

urologist, Ph. D. student at the Institute for Urology and Human Reproductive Health

Russian Federation, Moscow

Yu. V. Lerner

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: lerner_yu_v@staff.sechenov.ru

assistant at the Institute for Urology and Human Reproductive Health, Institute of clinical morphology and digital pathology

Russian Federation, Moscow

D. G. Tsarichenko

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: tsarichenkodg@yandex.ru

Ph.D., MD, professor, Director of the National Medical Research Center for «Urology», professor at the Institute for Urology and Human Reproductive Health, Institute of clinical morphology and digital pathology

Russian Federation, Moscow

M. A. Gazimiev

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: gazimiev_m_a@staff.sechenov.ru

Ph.D., MD, professor, Director of the Science and Technology Park for Biomedicine, Deputy Director on Science of the Institute for Urology and Human Reproductive Health of I.M. Sechenov First

Russian Federation, Moscow

L. M. Rapoport

FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: leonidrapoport@yandex.ru

Ph. D., MD, professor, Deputy Director on Medical care at the Institute of Urology and Reproductive Health

Russian Federation, Moscow

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
  2. The state of cancer care for the Russian population in 2022. Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. M.: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution «NMIC of Radiology» of the Ministry of Health of Russia, 2022. − fig. – 239 p. Russian (Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. − ил. – 239 с.).
  3. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer. 2008 Nov 15;113(10):2671-80. doi: 10.1002/cncr.23896. PMID: 18816624; PMCID: PMC2704569.
  4. Kwak K, Yu B, Lewandowski RJ, Kim DH. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics. 2022 Feb 14;12(5):2175-2204. doi: 10.7150/thno.67530. PMID: 35265206; PMCID: PMC8899563.
  5. Mastrandrea, Giovanni MDa; Laface, Carmelo MDb,c; Fazio, Vito MDb; Lopetuso, Marco TSMRd; Falagario, Gianmarco TSMRb; Molinari, Pasquale TSMRb; Ranieri, Girolamo MD, PhDb,∗; Gadaleta, Cosmo Damiano MDb. A case report of cryoablation and electrochemotherapy in kidney cancer. Medicine. 2021;100(45):e27730 doi: 10.1097/MD.000000000002773023:46
  6. Uchida M., Imaide Y., Sugimoto K. et al. Percutaneous cryosurgery for renal tumours. Br J Urol. 1995;75:132-136.
  7. Mazaris EM, Varkarakis IM, Solomon SB. Percutaneous renal cryoablation: current status. Future Oncol. 2008 Apr;4(2):257-69. doi: 10.2217/14796694.4.2.257. PMID: 18407738.
  8. Enikeev D.V. Glybochko P.V. Alyaev Yu.G. Rapoport L.M. Amosov A.V. Alekseeva T.M. Enikeev M.E. Tsarichenko D.G. Chinenov D.V., Kozmin L.D. Jalaev Z.K. Taratkin M.S. Percutaneous cryoablation of a kidney tumor under ultrasound control. Urology. 2017;3:68–73. Russian (Еникеев Д.В. Глыбочко П.В. Аляев Ю.Г. Рапопорт Л.М. Амосов А.В. Алексеева Т.М. Еникеев М.Э. Цариченко Д.Г. Чиненов Д.В., Козмин Л.Д., Джалаев З.К., Тараткин М.С. Чрескожная криоаблация опухоли почки под УЗ-контролем. Урология. 2017;3:68–73).
  9. Patel N, King AJ, Breen DJ. Percutaneous image-guided cryoablation of small renal masses. Abdominal radiology. 2016;41(4):754-66. doi: 10.1007/s00261-016-0682-2. PubMed PMID: 26915090.
  10. Gao H, Zhou L, Zhang J, Wang Q, Luo Z, Xu Q, Tan Y, Shuai H, Zhou J, Cai X, Zheng Y, Shan W, Duan X, Wu T. Comparative efficacy of cryoablation versus robot-assisted partial nephrectomy in the treatment of cT1 renal tumors: a systematic review and meta-analysis. BMC Cancer. 2024 Sep 16;24(1):1150. doi: 10.1186/s12885-024-12917-z. PMID: 39285347; PMCID: PMC11403780.
  11. Yanagisawa T, Mori K, Kawada T, Motlagh RS, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urol Oncol. 2022 Jul;40(7):315-330. doi: 10.1016/j.urolonc.2022.04.002. Epub 2022 May 11. PMID: 35562311.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure. Histological picture of postoperative material, stained with hematoxylin and eosin, magnification ×50 A — preserved kidney tissue, represented by single glomeruli and tubules with signs of epithelial dystrophy. Small petrification is determined. B — tumor pseudocapsule, represented by loose fibrous connective tissue with hyalinosis fields. B — necrotic detritus (formed after tumor cryodestruction) with cholesterol crystals and macrophages.

Download (231KB)

Copyright (c) 2024 Bionika Media